Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Oncoimmunology ; 12(1): 2244330, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37577144

RESUMO

Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes. While many of these immune evasion networks include checkpoint proteins, small molecular weight compounds, such as the amino acid L-kynurenine (LKU), could also substantially contribute to the suppression of anti-cancer immunity. However, the biochemical mechanisms underlying the suppressive effects of LKU on T-cells remain unclear. Here, we report for the first time that LKU suppresses T cell function as an aryl hydrocarbon receptor (AhR) ligand. The presence of LKU in T cells is associated with AhR activation, which results in competition between AhR and hypoxia-inducible factor 1 alpha (HIF-1α) for the AhR nuclear translocator, ARNT, leading to T cell exhaustion. The expression of indoleamine 2,3-dioxygenase 1 (IDO1, the enzyme that leads to LKU generation) is induced by the TGF-ß-Smad-3 pathway. We also show that IDO-negative cancers utilize an alternative route for LKU production via the endogenous inflammatory mediator, the high mobility group box 1 (HMGB-1)-interferon-gamma (IFN-γ) axis. In addition, other IDO-negative tumors (like T-cell lymphomas) trigger IDO1 activation in eosinophils present in the tumor microenvironment (TME). These mechanisms suppress cytotoxic T cell function, and thus support the tumor immune evasion machinery.


Assuntos
Cinurenina , Neoplasias , Humanos , Cinurenina/metabolismo , Cinurenina/farmacologia , Evasão da Resposta Imune , Transdução de Sinais , Linfócitos T , Microambiente Tumoral
2.
Oncotarget ; 6(30): 28678-92, 2015 Oct 06.
Artigo em Inglês | MEDLINE | ID: mdl-26384306

RESUMO

Correction of human myeloid cell function is crucial for the prevention of inflammatory and allergic reactions as well as leukaemia progression. Caffeine, a naturally occurring food component, is known to display anti-inflammatory effects which have previously been ascribed largely to its inhibitory actions on phosphodiesterase. However, more recent studies suggest an additional role in affecting the activity of the mammalian target of rapamycin (mTOR), a master regulator of myeloid cell translational pathways, although detailed molecular events underlying its mode of action have not been elucidated. Here, we report the cellular uptake of caffeine, without metabolisation, by healthy and malignant hematopoietic myeloid cells including monocytes, basophils and primary acute myeloid leukaemia mononuclear blasts. Unmodified caffeine downregulated mTOR signalling, which affected glycolysis and the release of pro-inflammatory/pro-angiogenic cytokines as well as other inflammatory mediators. In monocytes, the effects of caffeine were potentiated by its ability to inhibit xanthine oxidase, an enzyme which plays a central role in human purine catabolism by generating uric acid. In basophils, caffeine also increased intracellular cyclic adenosine monophosphate (cAMP) levels which further enhanced its inhibitory action on mTOR. These results demonstrate an important mode of pharmacological action of caffeine with potentially wide-ranging therapeutic impact for treating non-infectious disorders of the human immune system, where it could be applied directly to inflammatory cells.


Assuntos
Cafeína/farmacologia , Linhagem da Célula , Células Mieloides/efeitos dos fármacos , Serina-Treonina Quinases TOR/metabolismo , Xantina Oxidase/metabolismo , Proteínas Angiogênicas/metabolismo , Basófilos/efeitos dos fármacos , Basófilos/enzimologia , Cafeína/metabolismo , Linhagem Celular Tumoral , Citocinas/metabolismo , Relação Dose-Resposta a Droga , Regulação para Baixo , Glicólise/efeitos dos fármacos , Humanos , Mediadores da Inflamação/metabolismo , Leucemia Mieloide Aguda/enzimologia , Leucemia Mieloide Aguda/patologia , Monócitos/efeitos dos fármacos , Monócitos/enzimologia , Células Mieloides/enzimologia , Células Mieloides/patologia , Transdução de Sinais/efeitos dos fármacos
3.
Sci Rep ; 4: 6307, 2014 Sep 09.
Artigo em Inglês | MEDLINE | ID: mdl-25200751

RESUMO

Xanthine oxidase (XOD) is an enzyme which plays a central role in purine catabolism by converting hypoxanthine into xanthine and then further into uric acid. Here we report that XOD is activated in THP-1 human myeloid cells in response to pro-inflammatory and growth factor stimulation. This effect occurred following stimulation of THP-1 cells with ligands of plasma membrane associated TLRs 2 and 4, endosomal TLRs 7 and 8 as well as stem cell growth factor (SCF). Hypoxia-inducible factor 1 (HIF-1) and activator protein 1 (AP-1) transcription complexes were found to be responsible for XOD upregulation. Importantly, the mammalian target of rapamycin (mTOR), a major myeloid cell translation regulator, was also found to be essential for XOD activation. Specific inhibition of XOD by allopurinol and sodium tungstate led to an increase in intracellular AMP levels triggering downregulation of mTOR activation by phosphorylation of its T2446 residue. Taken together, our results demonstrate for the first time that XOD is not only activated by pro-inflammatory stimuli or SCF but also plays an important role in maintaining mTOR-dependent translational control during the biological responses of human myeloid cells.


Assuntos
Inflamação/imunologia , Células Mieloides/fisiologia , Serina-Treonina Quinases TOR/metabolismo , Xantina Oxidase/metabolismo , Alopurinol/farmacologia , Animais , Linhagem Celular Tumoral , Regulação para Baixo , Ativação Enzimática , Humanos , Subunidade alfa do Fator 1 Induzível por Hipóxia/genética , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Lipopolissacarídeos , Fígado/metabolismo , Células MCF-7 , Masculino , Camundongos , Peptidoglicano , Fosfatidilinositol 3-Quinases/metabolismo , Inibidores de Fosfoinositídeo-3 Quinase , Fosforilação , Interferência de RNA , RNA Interferente Pequeno , Fator de Células-Tronco/metabolismo , Receptor 2 Toll-Like/metabolismo , Receptor 4 Toll-Like/metabolismo , Receptor 7 Toll-Like/metabolismo , Receptor 8 Toll-Like/metabolismo , Fator de Transcrição AP-1/antagonistas & inibidores , Fator de Transcrição AP-1/metabolismo , Compostos de Tungstênio/farmacologia , Ácido Úrico/análise , Xantina Oxidase/antagonistas & inibidores , Xantina Oxidase/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...